Smith Karen L.
Known title: Chief Medical OfficerCIK: 0001639637
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 1, 2026
Quince Therapeutics LAM-001 Progress; Analyst Targets $70. Quince Therapeutics reported progress on its LAM-001 program for pulmonary hypertension and bronchiolitis obliterans syndrome. A new analyst coverage was launched with a buy rating and a $70 price target. The company’s stock is trading near its 12‑touch support level of $17.70 and shows a moderate RSI of 55.9, indicating balanced momentum.
Transaction History
| AUPH | ▲ Buy | Grant | 12,135 | $0 | 11/21/2024 | View on chart |
| AUPH | ▼ Sell | Open Market | 5,241 | $44K | 11/11/2024 | View on chart |
| AUPH | ▲ Buy | Option Exercise | 17,913 | — | 11/8/2024 | View on chart |
| QNCX | ▲ Buy | Grant | 24,336 | — | 5/19/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 7, 2026
AUPH Appears in Report on Activist Investor Activity
Aurinia Pharmaceuticals was mentioned among stocks drawing attention from activist investors, according to recent financial news coverage. No specific activist involvement details or corporate action plans were detailed in the report. The stock is currently trading between its 52-week range extremes, with analysts maintaining price targets notably above current levels.
AUPH Appears in Report on Activist Investor Activity. Aurinia Pharmaceuticals was mentioned among stocks drawing attention from activist investors, according to recent financial news coverage. No specific activist involvement details or corporate action plans were detailed in the report. The stock is currently trading between its 52-week range extremes, with analysts maintaining price targets notably above current levels.